Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by longrun86on Mar 19, 2024 6:52pm
138 Views
Post# 35941803

RE:Next Earnings - 2024/03/21

RE:Next Earnings - 2024/03/21The fun begins!

I am expecting that some fairly material insights into FY2024 and especially regarding the revenue and operating margin growth. 

I am also hopeful that they will be able to provide further commentary on the business development efforts outside of the organic product launches.

Currencies will continue to be a wild card and the devaluation in Argentina was pretty extreme in 2023. My hope is that Argentina will get its act together.

It would be nice to see them stitch together a decent Q4 2023 and give some confidence around the growth in 2024. Investors (the ones who are still left here) want to see growth in the platform and thats what they need to deliver on.

There has been some discussion regarding an expansion out of South America but I don't think they are firing on all cylinders there yet. Perhaps a few deals in Canada that are attractive, but at this time I would be wary of them expanding too far afield.

Just my hopeful musings!

LR
<< Previous
Bullboard Posts
Next >>